Bio Solution Co., Ltd.

As of June 30, 2026, Bio Solution Co., Ltd. carries a market capitalization of 162.57B, placing it among publicly traded companies globally. Its enterprise value stands at 170.09B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Bio Solution Co., Ltd. has 25.80M shares outstanding.

As of June 30, 2026, Bio Solution Co., Ltd. trades at a trailing price-to-earnings ratio of 178.06. The price-to-sales ratio is 8.90, and the price-to-book ratio stands at 3.94.

These figures are as of June 30, 2026. The EV/Sales ratio of 9.78 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Bio Solution Co., Ltd. trades at an EV/FCF ratio of 74.64, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 170.09B versus a market cap of 162.57B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Bio Solution Co., Ltd. maintains a current ratio of 0.84, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 46.36, indicating elevated leverage, while an interest coverage ratio of -0.40 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Bio Solution Co., Ltd. posted a return on equity (ROE) of 2.50, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -5.75, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 1.34, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 5.88, useful for judging operating efficiency across full business cycles. The company generates approximately 179.32M in revenue per employee across its workforce of 97.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.33 indicates how many times Bio Solution Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, Bio Solution Co., Ltd.'s stock has declined approximately 27.23% over the past 52 weeks. The 50-day moving average sits at 6,448.80, while the 200-day moving average is 8,112.65.

Over the twelve months ended June 30, 2026, Bio Solution Co., Ltd. generated 17.39B in revenue and converted that into 868.96M in net income, yielding earnings per share of 35.38. EBITDA reached -1.04B, while operating income came in at -3.37B.

As of June 30, 2026, Bio Solution Co., Ltd. holds 11.62B in cash and equivalents against 19.15B in total debt, resulting in a net debt position of 9.39B. Total book value stands at 41.31B, with working capital of -3.65B providing operational flexibility.

Bio Solution Co., Ltd. produced -46.36M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -266.61M in capital expenditures, free cash flow totaled -312.97M - equivalent to -12.74 per share.

Over the twelve months ended June 30, 2026, Bio Solution Co., Ltd. posted a gross margin of 65.65, reflecting its pricing power and cost economics. The operating margin of -19.35 and net profit margin of 5.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.20: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.51, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bio Solution Co., Ltd. shareholders.

Bio Solution Co., Ltd.'s most recent stock split took place on May 27, 2025 with a 1:3 split ratio.

As of June 30, 2026, Bio Solution Co., Ltd. has an Altman Z-Score of 3.03, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.